Skip to main content
FUTURA MEDICAL PLC logo

FUTURA MEDICAL PLC — Investor Relations & Filings

Ticker · FUM ISIN · GB0033278473 LEI · 21380053QLT46UNV2303 IL Manufacturing
Open in API
Filings indexed 571 across all filing types
Latest filing 2026-04-29 Earnings Release
Country GB United Kingdom
Listing IL FUM

About FUTURA MEDICAL PLC

https://www.futuramedical.com/

Futura Medical is a pharmaceutical company specializing in the research, development, and global commercialization of innovative sexual health products. The company's core strength is its expertise in proprietary, topically delivered gel formulations. Its lead product, Eroxon®, is a clinically proven, fast-acting topical gel for the treatment of erectile dysfunction (ED). Eroxon® is distinguished by its rapid onset of action, helping users achieve an erection within 10 minutes, and is available over-the-counter in major markets including the USA and Europe. The company utilizes a de-risked commercialization strategy, establishing partnerships with leading consumer healthcare companies for distribution and marketing. Futura Medical's development pipeline also includes potential treatments for female sexual dysfunction.

Recent filings

Filing Released Lang Actions
Unaudited Results for the Year Ended 31 Dec 2025
Earnings Release Classification · 1% confidence The document is an unaudited results announcement titled “Unaudited Results for the Year Ended 31 December 2025” and comprises key financial highlights (revenue, operating loss, cash position), operational/strategic overviews, CEO/Chairman commentary and outlook. It is clearly an initial earnings announcement rather than a full annual report, audit, or other regulatory filing. Therefore, it matches the Earnings Release category (ER). FY 2025
2026-04-29 English
Notice of Results & Investor Presentation
Report Publication Announcement Classification · 1% confidence The document is an RNS announcement titled “Notice of Results & Investor Presentation” advising of the upcoming full year results release date and webinar details. It does not contain the actual financial results or detailed report content, but rather announces the timing and availability of the report and presentation. Under the “menu vs meal” rule, this is a report publication announcement rather than the report itself.
2026-04-20 English
Positive Eroxon® & Eroxon® “Intense” HUT results
Regulatory Filings Classification · 1% confidence The document is an RNS press release announcing clinical trial results for Eroxon products. It does not contain financial statements or earnings data, nor is it soliciting votes, reporting voting results, or detailing governance or management changes. It is not a regulatory compliance report like a 10-K/10-Q, but a market news release distributed via the London Stock Exchange’s RNS service. Therefore, the appropriate category is the general Regulatory Filings (RNS) fallback.
2026-03-23 English
Formal Grant of US Patent
Regulatory Filings Classification · 1% confidence The document is a regulatory announcement issued via the London Stock Exchange's RNS (Regulatory News Service). It details the formal grant of a US patent for the company's product, Eroxon, and mentions a resulting milestone payment. Since this is a general corporate announcement regarding business operations and intellectual property that does not fit into specific categories like financial reports, dividends, or director dealings, it is classified as a general regulatory filing.
2026-03-18 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is a 'TR-1: Standard form for notification of major holdings', which is the regulatory standard in the UK for reporting changes in significant share ownership. It explicitly identifies the issuer (Futura Medical plc), the person subject to the notification (Mr R McAlpine), and the percentage of voting rights held (3.44%). This fits the definition of a Major Shareholding Notification (MRQ).
2026-03-17 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is a 'TR-1: Standard form for notification of major holdings' filed by Lombard Odier Asset Management regarding Futura Medical PLC. This document explicitly details a change in significant share ownership (crossing a threshold from 10.96% to 9.84%), which aligns perfectly with the definition of a Major Shareholding Notification.
2026-02-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.